Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BYJournal of clinical medicine

Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib

  • Piotr Kawczak1
  • Tomasz Bączek1
  1. 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdansk, Poland;
Read full textPDFCite

Related

  1. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
    Tanios Bekaii‐Saab, Davide Melisi, Hanneke W. Wilmink +24
    Journal of Clinical OncologyPeer-reviewedLicence not statedFull text10 citedSurgery & anaesthesiaOpenAlex
  2. Integrated multi-omics analysis reveals that tumour cell-intrinsic DCLK1 is associated with an angiogenic tumour microenvironment in cholangiocarcinoma via NF-κB/CXCL5
    Ziqing Kong, Rui Yan, Ziwei Liang +2
    Journal of Cancer Research and Clinical OncologyPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaPMC
  3. NETs and the thrombo-immune microenvironment: immune heterogeneity in recanalization, reperfusion, hemorrhagic transformation, and antithrombotic strategies
    Fangfang Zhu, Feng Wang, Shuhua Wang +2
    Frontiers in neurologyPeer-reviewedCC BYFull textNeurologyEurope PMC
  4. Strategies of mechanical adaptations of circulating tumor cells and properties of their cellular microenvironment have predictive and prognostic biomarker value
    M. Gaczynska, F. Ataei, C.-W. Chou +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. JAK-STAT signaling: a key mechanism of immune microenvironment remodeling in breast cancer and novel strategies for targeted therapy
    Junfang Qiao, Tingting Sun, Guoqiang Wang +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{kawczak2026molecularly,
  title = {{Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib}},
  author = {Piotr Kawczak and Tomasz Bączek},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13665538},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib
AU  - Piotr Kawczak
AU  - Tomasz Bączek
PY  - 2026
DA  - 2026/09/23
JO  - Journal of clinical medicine
UR  - https://europepmc.org/article/PMC/PMC13665538
SN  - 2077-0383
ER  -